bioAffinity Technologies (NASDAQ:BIAF) Now Covered by Maxim Group

Maxim Group began coverage on shares of bioAffinity Technologies (NASDAQ:BIAF) in a report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $6.00 price objective on the stock.

bioAffinity Technologies Stock Performance

bioAffinity Technologies stock opened at $2.68 on Tuesday. The company has a current ratio of 2.22, a quick ratio of 2.21 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $2.30 and a 200-day moving average of $2.09. The stock has a market cap of $31.25 million, a P/E ratio of -2.88 and a beta of 2.99. bioAffinity Technologies has a 52 week low of $0.95 and a 52 week high of $3.62.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.21) earnings per share for the quarter. bioAffinity Technologies had a negative return on equity of 134.34% and a negative net margin of 171.43%. The company had revenue of $2.41 million for the quarter.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.